Patents Assigned to Noxxon Pharma AG
-
Publication number: 20130041019Abstract: The present invention is related to an L nucleic acid that binds to an SDF-1.Type: ApplicationFiled: October 13, 2012Publication date: February 14, 2013Applicant: NOXXON Pharma AGInventor: NOXXON Pharma AG
-
Publication number: 20130035376Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3 nucleic acids, Type 4 nucleic acids and nucleic acids comprising SEQ ID NOs:87-115Type: ApplicationFiled: June 4, 2012Publication date: February 7, 2013Applicant: NOXXON PHARMA AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Patent number: 8367629Abstract: The present invention is related to a nucleic acid molecule capable of binding to MCP-1, whereby the nucleic acid molecule is for use as a medicament for the treatment and/or prevention of a chronic disease or chronic disorder, preferably selected from the group consisting of chronic respiratory disease, chronic kidney disease and systemic lupus erythematosus.Type: GrantFiled: November 29, 2008Date of Patent: February 5, 2013Assignee: NOXXON Pharma AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Patent number: 8314223Abstract: The present invention is related to a nucleic acid molecule, preferably binding to SDF-1, selected from the group comprising type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ ID NO:142, SEQ ID NO:143 or SEQ ID NO:144.Type: GrantFiled: January 18, 2009Date of Patent: November 20, 2012Assignee: NOXXON Pharma AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
-
Publication number: 20120258457Abstract: The present invention is related to a method for the detection of a nucleic acid molecule comprising at least a strand comprising a sequence of nucleotides in a sample, whereby the method comprises the following steps: providing a sample containing the nucleic acid molecule; providing a capture probe, whereby the capture probe is at least partially complementary to a part of the nucleic acid molecule; allowing the capture probe to react with the nucleic acid molecule or a part thereof; and detecting whether or not the capture probe is hybridized to the nucleic acid molecule or part thereof.Type: ApplicationFiled: April 22, 2012Publication date: October 11, 2012Applicant: NOXXON PHARMA AGInventors: Florian Jarosch, Hilke Hansen, Christian Lange
-
Patent number: 8193159Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ. ID. No. 87 to 115.Type: GrantFiled: February 14, 2007Date of Patent: June 5, 2012Assignee: NOXXON Pharma AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Publication number: 20120115937Abstract: The present invention is related to a nucleic acid, preferably binding to ghrelin, whereby the nucleic acid comprises a first stretch Box A, and a second stretch Box B, whereby the first stretch Box A comprises about 25 consecutive nucleotides, the second stretch Box B comprises about six to eight consecutive nucleotides, whereby a 3?-terminal stretch of nucleotides of the first stretch Box A hybridises with the second stretch Box B, whereby upon hybridisation a first double-stranded structure is formed, whereby such first double-stranded structure comprises a bulge.Type: ApplicationFiled: January 24, 2012Publication date: May 10, 2012Applicant: NOXXON PHARMA AGInventors: Florian Jarosch, Dirk Eulberg, Christian Maasch, Steffen Helmling, Sven Klussmann
-
Publication number: 20120083520Abstract: The present invention is related to a nucleic acid antagonist of ghrelin.Type: ApplicationFiled: May 8, 2010Publication date: April 5, 2012Applicant: NOXXON PHARMA AGInventors: Steffen Helmling, Dirk Eulberg, Christian Maasch, Sven Klussmann
-
Publication number: 20120065254Abstract: The present invention is related to a nucleic acid molecule, capable of binding to C5a, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of tumors, the treatment and/or prevention of a respiratory disease, the treatment and/or prevention of pain and/or the treatment and/or prevention of a neurodegenerative disorder.Type: ApplicationFiled: March 23, 2010Publication date: March 15, 2012Applicant: NOXXON PHARMA AGInventors: Florian Jarosch, Werner Purschke, Dirk Eulberg, Christian Maasch, Klaus Buchner, Sven Klussmann
-
Publication number: 20120053234Abstract: The present invention is related to a nucleic acid capable of binding to hepcidin.Type: ApplicationFiled: April 30, 2010Publication date: March 1, 2012Applicant: NOXXON PHARMA AGInventors: Simone Sell, Frank Morich, Christian Maasch, Sven Klussmann, Nicole Dinse, Klaus Buchner, Frank Schwobel
-
Patent number: 8101734Abstract: The present invention is related to a nucleic acid, preferably binding to ghrelin, whereby the nucleic acid comprises a first stretch Box A, and a second stretch Box B, whereby the first stretch Box A comprises about 25 consecutive nucleotides, the second stretch Box B comprises about six to eight consecutive nucleotides, whereby a 3?-terminal stretch of nucleotides of the first stretch Box A hybridizes with the second stretch Box B, whereby upon hybridization a first double-stranded structure is formed, whereby such first double-stranded structure comprises a bulge.Type: GrantFiled: April 7, 2006Date of Patent: January 24, 2012Assignee: NOXXON Pharma AGInventors: Florian Jarosch, Dirk Eulberg, Christian Maasch, Steffen Helmling, Sven Klussmann
-
Publication number: 20110229976Abstract: The present invention is related to a method for determining the nucleotide sequence of a nucleic acid molecule comprising the following steps: a) providing a plurality of molecules of the nucleic acid molecule having at least one modification; b) cleaving at random the plurality of modified nucleic acid molecules thus providing modified nucleic acid molecule fragments and non-modified nucleic acid molecule fragments; c) separating the modified nucleic acid molecule fragments from the non-modified nucleic acid molecule fragments; d) separating or resolving the modified nucleic acid molecule fragments according to their length, mass and/or charge, whereby such separating or resolving generates a pattern of modified nucleic acid fragments; and e) optionally visualizing the pattern of modified nucleic acid fragments.Type: ApplicationFiled: October 29, 2009Publication date: September 22, 2011Applicant: NOXXON PHARMA AGInventors: John Turner, Johannes Hoos, Sven Klussmann
-
Publication number: 20110223127Abstract: The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.Type: ApplicationFiled: August 6, 2008Publication date: September 15, 2011Applicant: NOXXON PHARMA AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
-
Publication number: 20110112172Abstract: The present invention is related to a nucleic acid molecule, preferably binding to SDF-1, selected from the group comprising type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ ID NO:142, SEQ ID NO:143 or SEQ ID NO:144.Type: ApplicationFiled: January 18, 2009Publication date: May 12, 2011Applicant: NOXXON PHARMA AGInventors: WERNER PURSCHKE, FLORIAN JAROSCH, DIRK EULBERG, SVEN KLUSSMANN, KLAUS BUCHNER, CHRISTIAN MAASCH, NICOLE DINSE
-
Publication number: 20110046207Abstract: The present invention is related to a nucleic acid, preferably binding to C5a, selected from the group comprising type A nucleic acids, type B nucleic acids, type C nucleic acids, type D nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 73 to 79.Type: ApplicationFiled: September 24, 2008Publication date: February 24, 2011Applicant: NOXXON PHARMA AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Publication number: 20110027794Abstract: The invention relates to a method for synthesizing a nucleic acid containing modified nucleotides. The method encompasses the following steps: a matrix strand is provided; —a primer which at least partially hybridizes on the matrix strand is provided; —nucleoside triphosphates, at least some of which are modified nucleoside triphosphates, are provided; —a polymerase activity is supplied; and—the matrix strand, the primer, and the nucleoside triphosphates are incubated so as to synthesize a nucleic acid that is substantially complementary to the matrix strand. The polymerase activity can be a reverse transcriptase activity.Type: ApplicationFiled: October 15, 2010Publication date: February 3, 2011Applicant: NOXXON PHARMA AGInventors: Sven Klussmann, Florian Jarosch, Axel Vater
-
Patent number: 7879991Abstract: The invention relates to an antagonist for CGRP and amylin, whereby the antagonist is a nucleic acid and said nucleic acid binds to CGRP or amylin. Said nucleic acid preferably comprises an L-nucleotide.Type: GrantFiled: May 6, 2003Date of Patent: February 1, 2011Assignee: NOXXON Pharma AGInventors: Axel Vater, Christian Maasch, Florian Jarosch, Mathias Bell, Steffen Helmling, Bernd Eschgfäller, Elisabeth Moyroud, Sandra Stark, Sven Klussmann, Thorsten Ruppert, Gregor Bahrenberg, Clemens Gillen, Klaus Schiene
-
Publication number: 20100311816Abstract: Nucleic acid molecules that bind MCP-1 can be used for treating or preventing chronic diseases, such as, respiratory disease, kidney disease or system lupus erythematosus.Type: ApplicationFiled: November 29, 2008Publication date: December 9, 2010Applicant: Noxxon Pharma AGInventor: Werner Purschke
-
Publication number: 20100284961Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ. ID. No. 87 to 115.Type: ApplicationFiled: February 14, 2007Publication date: November 11, 2010Applicant: NOXXON PHARMA AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Publication number: 20100261291Abstract: The present invention is related to a nucleic acid specifically binding bioactive ghrelin, more preferably n-octanoyl ghrelin, and its use for the diagnosis of ghrelin mediated diseases and disorders.Type: ApplicationFiled: February 24, 2010Publication date: October 14, 2010Applicant: NOXXON Pharma AGInventors: SVEN KLUSSMANN, STEFFEN HELMLING, DIRK EULBERG, CHRISTIAN MAASCH, KLAUS BUCHNER